Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
February 08, 2021 07:30 ET | Source: Dyne Therapeutics, Inc. Dyne Therapeutics, Inc. Waltham, Massachusetts, UNITED STATES
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease
WALTHAM, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Ashish Dugar, Ph.D., MBA, as senior vice president, global head of medical affairs. Dr. Dugar brings over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation.
Share this article
Share this article
NEW YORK, Feb. 4, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ( Sarepta or the Company )(NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 7, 2021, Sarepta issued a press release announcing top-line results for Part 1 of the Company s Study SRP-9001-102 ( Study 102 ), an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in 41 patients with Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue fo
Gain Therapeutics
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board.
Biogen Alzheimer’s drug puts FDA’s judgment in harsh spotlight
Biogen Inc. said Friday, Jan. 29, that the U.S. Food and Drug Administration is extending its review of aducanumab, an experimental therapy that patients and their families see as a potential lifeline.
Written By:
Anna Edney / Bloomberg News | 7:45 am, Feb. 2, 2021 ×
A sign for biotechnology company, Biogen, Inc., is seen on a building in Cambridge, Mass., on March 18, 2017. (Dominick/AFP/Getty Images/TNS)
WASHINGTON (Tribune News Service) A new drug for Alzheimer’s disease is on a tortuous path toward the U.S. market, and while many patients would hail approval as a major advance, it could also revive concerns about regulators’ scientific integrity.
Biogen Alzheimer’s drug puts FDA’s judgment in harsh spotlight
Biogen Inc. said Friday, Jan. 29, that the U.S. Food and Drug Administration is extending its review of aducanumab, an experimental therapy that patients and their families see as a potential lifeline.
Written By:
Anna Edney / Bloomberg News | 7:45 am, Feb. 2, 2021 ×
A sign for biotechnology company, Biogen, Inc., is seen on a building in Cambridge, Mass., on March 18, 2017. (Dominick/AFP/Getty Images/TNS)
WASHINGTON (Tribune News Service) A new drug for Alzheimer’s disease is on a tortuous path toward the U.S. market, and while many patients would hail approval as a major advance, it could also revive concerns about regulators’ scientific integrity.